Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
10.49
-0.30 (-2.78%)
At close: Oct 8, 2025, 4:00 PM EDT
10.52
+0.03 (0.29%)
After-hours: Oct 8, 2025, 4:24 PM EDT
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
32
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,706,625
Market Cap
171.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32 | 0 | - |
| Dec 31, 2023 | 32 | 9 | 39.13% |
| Dec 31, 2022 | 23 | -1 | -4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELTX News
- 9 days ago - Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 20 days ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 21 days ago - Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis - GlobeNewsWire
- 4 months ago - Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Secures $10 Million in Financing - GlobeNewsWire